Connect Biopharma’s (CNTB) Buy Rating Reiterated at HC Wainwright

Posted by Brenda Bartman on Oct 8th, 2026

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday, MarketBeat.com reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

CNTB has been the topic of a number of other research reports. BTIG Research lowered their price objective on shares of Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Weiss Ratings upgraded shares of Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. Oppenheimer lowered their price objective on shares of Connect Biopharma to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 22nd. Piper Sandler initiated coverage on shares of Connect Biopharma in a report on Friday, June 26th. They set an “overweight” rating and a $7.00 target price for the company. Finally, Wall Street Zen raised shares of Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.14.

Read Our Latest Research Report on Connect Biopharma

Connect Biopharma Stock Performance

Connect Biopharma stock traded down $0.06 during midday trading on Thursday, reaching $0.88. 1,210,032 shares of the company traded hands, compared to its average volume of 1,441,842. The firm has a market capitalization of $55.46 million, a price-to-earnings ratio of -0.74 and a beta of -0.16. The business has a 50 day moving average of $1.83 and a two-hundred day moving average of $2.23. Connect Biopharma has a 12 month low of $0.85 and a 12 month high of $3.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. The company had revenue of $2.75 million for the quarter, compared to the consensus estimate of $0.74 million. As a group, research analysts predict that Connect Biopharma will post -1.09 earnings per share for the current year.

Institutional Trading of Connect Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC purchased a new stake in shares of Connect Biopharma in the first quarter worth $1,945,000. Knott David M Jr increased its stake in shares of Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares in the last quarter. Richmond Brothers Inc. purchased a new stake in shares of Connect Biopharma in the fourth quarter worth $489,000. Simplify Asset Management Inc. purchased a new stake in shares of Connect Biopharma in the first quarter worth $135,000. Finally, Bank of America Corp DE purchased a new stake in shares of Connect Biopharma in the first quarter worth $41,000. 58.72% of the stock is owned by hedge funds and other institutional investors.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.